DIAGNOSTICS AND CORRECTION OF THROMBOHEMORRHAGIC DISORDERS IN PATIENTS WITH GIANT UTERINE MYOMA AT THE PERIOPERATIVE STAGE OF TREATMENT.
O A TarabrinI I TyutrinD G GavrichenkovS S ShcherbakovA I MazurenkoA V TurenkoPublished in: Anesteziologiia i reanimatologiia (2018)
The aim of the study was to reduce perioperative blood loss in patients with giant uterine myoma. As a result of studies have provided evidence that the use of anti fibrinolytic therapy as intravenous infusion of tranexamic acid for 30 minutes before the surgery in a dose of 20 mg/kg followed by infusion of 5 mg/kg per hour for the first postoperative day, helped to reduce perioperative blood loss by 29%. Hemoglobin level was higher by 10% (p < 0,05), blood loss was lower by 29% (p < 0,05), the length of stay in hospital was reduced by 24% (p < 0,05) in patients of the second group on the second postoperative day.
Keyphrases
- patients undergoing
- cardiac surgery
- end stage renal disease
- low dose
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- healthcare
- blood pressure
- high dose
- prognostic factors
- stem cells
- coronary artery bypass
- acute kidney injury
- coronary artery disease
- patient reported
- acute care
- case control
- adverse drug